NICOX
Nicox is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Their lead program in the ophthalmic pipeline, NCX 470, is currently in Phase 3 clinical development targeting glaucoma. Their ophthalmic pipeline also includes a candidate under preclinical evaluation for development in retinal conditions, NCX 1728, and a clinical-stage product candidate for dry eye disease licensed exclusively to a partner for the Chinese market, NCX 4251.
They have two products commercialized in the U.S.: VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% for open-angle glaucoma and ZERVIATE® (cetirizine ophthalmic solution) 0.24% for ocular allergic conjunctivitis. These products are being rolled out in territories outside of the U.S. through partnerships.
NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop targeting glaucoma that leverages the potent intraocular pressure (IOP)-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule. The first of two Phase 3 trials for NCX 470, Mont Blanc, met the efficacy requirements for approval in the U.S. The similarly designed and ongoing second Phase 3 trial, Denali, conducted at clinical sites in the U.S. and China is ongoing with topline results are expected in H2 2025.
– Therapeutic areas: Ophthalmology
– Based in: Sophia Antipolis (FRANCE), Durham (USA)
– Employees: 11 – 50
– Created in: 1996
